TW202511296A - 抗trem2抗體及其使用方法 - Google Patents
抗trem2抗體及其使用方法 Download PDFInfo
- Publication number
- TW202511296A TW202511296A TW113146124A TW113146124A TW202511296A TW 202511296 A TW202511296 A TW 202511296A TW 113146124 A TW113146124 A TW 113146124A TW 113146124 A TW113146124 A TW 113146124A TW 202511296 A TW202511296 A TW 202511296A
- Authority
- TW
- Taiwan
- Prior art keywords
- al2p
- amino acid
- antibody
- trem2
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762541019P | 2017-08-03 | 2017-08-03 | |
| US62/541,019 | 2017-08-03 | ||
| US201862636095P | 2018-02-27 | 2018-02-27 | |
| US62/636,095 | 2018-02-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202511296A true TW202511296A (zh) | 2025-03-16 |
Family
ID=63364160
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113146124A TW202511296A (zh) | 2017-08-03 | 2018-08-02 | 抗trem2抗體及其使用方法 |
| TW107126810A TWI811229B (zh) | 2017-08-03 | 2018-08-02 | 抗trem2抗體及其使用方法 |
| TW112126799A TWI868807B (zh) | 2017-08-03 | 2018-08-02 | 抗trem2抗體及其使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW107126810A TWI811229B (zh) | 2017-08-03 | 2018-08-02 | 抗trem2抗體及其使用方法 |
| TW112126799A TWI868807B (zh) | 2017-08-03 | 2018-08-02 | 抗trem2抗體及其使用方法 |
Country Status (34)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2017001531A (es) | 2014-08-08 | 2017-05-15 | Alector Llc | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
| US10428143B2 (en) | 2014-09-28 | 2019-10-01 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| RS64419B1 (sr) | 2017-08-03 | 2023-09-29 | Alector Llc | Anti-trem2 antitela i postupci za njihovu upotrebu |
| EP3723803A4 (en) | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES |
| MA54296A (fr) | 2018-11-26 | 2021-10-06 | Denali Therapeutics Inc | Procédés de traitement du métabolisme lipidique dérégulé |
| EP3927743A1 (en) | 2019-02-20 | 2021-12-29 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| WO2021101823A1 (en) * | 2019-11-22 | 2021-05-27 | Eli Lilly And Company | Trem2 antibodies and uses thereof |
| WO2021113655A1 (en) | 2019-12-05 | 2021-06-10 | Alector Llc | Methods of use of anti-trem2 antibodies |
| CN115279790A (zh) | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| WO2021146256A1 (en) | 2020-01-13 | 2021-07-22 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| CA3167851A1 (en) * | 2020-02-24 | 2021-09-02 | Francesca CIGNARELLA | Methods of use of anti-trem2 antibodies |
| EP4126953A2 (en) * | 2020-04-03 | 2023-02-08 | Alector LLC | Methods of use of anti-trem2 antibodies |
| TW202306993A (zh) | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Ｔｒｅｍ２之促效劑 |
| TW202340235A (zh) | 2021-12-17 | 2023-10-16 | 美商戴納立製藥公司 | 多肽工程、文庫及工程ｃｄ９８重鏈以及轉鐵蛋白受體結合多肽 |
| EP4482523A1 (en) | 2022-02-23 | 2025-01-01 | Alector LLC | Methods of use of anti-trem2 antibodies |
| WO2023192288A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Monovalent anti-trem2 binding molecules and methods of use thereof |
| WO2023192282A1 (en) | 2022-03-28 | 2023-10-05 | Denali Therapeutics Inc. | Methods for treating brain glucose hypometabolism |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| JP2025529287A (ja) | 2022-09-06 | 2025-09-04 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | マルファン症候群の処置のためのｔｒｅｍ－２アゴニスト |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2024253420A1 (ko) * | 2023-06-09 | 2024-12-12 | 재단법인대구경북과학기술원 | 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도 |
| TW202515919A (zh) | 2023-09-01 | 2025-04-16 | 比利時商艾托斯比利時公司 | 抗ｔｒｅｍ２抗體及使用方法 |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025166058A1 (en) * | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific proteins that bind to trem2 and transferrin receptor and uses therefor |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| CN117964768B (zh) * | 2024-04-02 | 2024-06-28 | 上海宏成药业有限公司 | 抗trem2抗体及其用途 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (118)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| DK187280A (da) | 1980-04-30 | 1981-10-31 | Novo Industri As | Ruhedsreducerende middel til et fuldvaskemiddel fuldvaskemiddel og fuldvaskemetode |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| JP2938569B2 (ja) | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル，インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| CA2140280A1 (en) | 1992-08-17 | 1994-03-03 | Avi J. Ashkenazi | Bispecific immunoadhesins |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| JP2002514895A (ja) | 1995-09-28 | 2002-05-21 | アレクション、ファーマスーティカルズ、インコーポレーテッド | ブタ細胞相互作用タンパク質 |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| ES2301183T3 (es) | 1996-12-03 | 2008-06-16 | Amgen Fremont Inc. | Anticuerpo completamente humano que se une al receptor del egfr. |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| ATE531812T1 (de) | 1997-12-05 | 2011-11-15 | Scripps Research Inst | Humanisierung von nager-antikörpern |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| EP1090118A2 (en) | 1998-06-26 | 2001-04-11 | Incyte Pharmaceuticals, Inc. | Human signal peptide-containing proteins |
| EP1222292B1 (en) | 1999-10-04 | 2005-08-31 | Medicago Inc. | Method for regulating transcription of foreign genes in the presence of nitrogen |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6849425B1 (en) * | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| PT2857516T (pt) | 2000-04-11 | 2017-08-28 | Genentech Inc | Anticorpos multivalentes e utilizações dos mesmos |
| US8231878B2 (en) | 2001-03-20 | 2012-07-31 | Cosmo Research & Development S.P.A. | Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| CA2342376C (en) | 2001-03-20 | 2013-11-12 | Marco Colonna | A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| US8981061B2 (en) | 2001-03-20 | 2015-03-17 | Novo Nordisk A/S | Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof |
| US20090081199A1 (en) | 2001-03-20 | 2009-03-26 | Bioxell S.P.A. | Novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof |
| EP2316485A1 (en) | 2001-10-12 | 2011-05-04 | Schering Corporation | Use of bispecific antibodies to regulate immune responses |
| EP1508340A4 (en) | 2002-05-24 | 2009-07-01 | Takeda Pharmaceutical | MEANS FOR IMPROVING INSULIN RESISTANCE |
| JP2004073182A (ja) | 2002-05-24 | 2004-03-11 | Takeda Chem Ind Ltd | インスリン抵抗性改善剤 |
| US20060263774A1 (en) | 2002-11-01 | 2006-11-23 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004042072A2 (en) | 2002-11-01 | 2004-05-21 | The Regents Of The University Of Colorado, A Body Corporate | Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry |
| CA2506672C (en) | 2002-12-23 | 2012-04-17 | Schering Corporation | Il-23 for treating cutaneous wounds |
| WO2004074506A2 (en) | 2003-02-13 | 2004-09-02 | Mergen Ltd | Polynucleotide sequences and corresponding encoded polypeptides of particular secreted and membrane-bound proteins overexpressed in certain cancers |
| US20080181888A1 (en) | 2004-12-31 | 2008-07-31 | Ambrose Christine M | Polypeptides That Bind Br3 and Uses Thereof |
| US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
| US8101345B1 (en) | 2005-03-25 | 2012-01-24 | Isis Pharmaceuticals, Inc. | Proinflammatory nucleic acids |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| WO2007106585A1 (en) | 2006-03-15 | 2007-09-20 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
| DE202006007499U1 (de) | 2006-05-11 | 2007-01-11 | Osaka University | Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen |
| MX380352B (es) | 2006-06-12 | 2025-03-12 | Aptevo Res & Development Llc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
| WO2008042261A2 (en) * | 2006-09-28 | 2008-04-10 | Elusys Therapeutics, Inc. | Anti-anthrax antibody, formulations thereof, and methods of use |
| US7673853B2 (en) | 2006-10-12 | 2010-03-09 | Cordell Eldred Ebeling | Fencing section with adjustable fencing members |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| EP2121750A2 (en) * | 2007-01-16 | 2009-11-25 | Wyeth | Inflammation treatment, detection and monitoring via trem-1 |
| CN101855242B (zh) | 2007-09-14 | 2014-07-30 | 阿迪马布有限责任公司 | 合理设计的合成抗体文库及其用途 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2195344A4 (en) | 2007-10-05 | 2011-07-06 | Univ Maryland | NEW COMPOSITIONS AND METHODS FOR STIMULATING ERYTHROPOIESE IN A MAMMALIAN |
| KR100960684B1 (ko) | 2008-02-22 | 2010-05-31 | 전남대학교산학협력단 | Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법 |
| EP2186928A1 (en) | 2008-11-14 | 2010-05-19 | Enthone, Inc. | Method for the post-treatment of metal layers |
| FR2945538B1 (fr) | 2009-05-12 | 2014-12-26 | Sanofi Aventis | Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide. |
| WO2011047097A2 (en) | 2009-10-13 | 2011-04-21 | Sigalov Alexander B | Inhibition of trem receptor signaling with peptide variants |
| US10584181B2 (en) | 2009-12-04 | 2020-03-10 | Genentech, Inc. | Methods of making and using multispecific antibody panels and antibody analog panels |
| TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究（慕尼黑）有限責任公司 | 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體 |
| EP3336225B1 (en) | 2010-07-16 | 2020-02-19 | Adimab, LLC | Antibody libraries |
| UA112062C2 (uk) | 2010-10-04 | 2016-07-25 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Cd33-зв'язувальний агент |
| WO2012088302A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Half immunoglobulin binding proteins and uses thereof |
| UY33826A (es) | 2010-12-22 | 2012-07-31 | Abbott Lab | Proteínas de unión con dominios trivariables y sus usos |
| AR087744A1 (es) * | 2011-09-01 | 2014-04-16 | Sanofi Aventis Deutschland | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa |
| US20130309223A1 (en) | 2012-05-18 | 2013-11-21 | Seattle Genetics, Inc. | CD33 Antibodies And Use Of Same To Treat Cancer |
| WO2014074942A1 (en) | 2012-11-08 | 2014-05-15 | Illumina, Inc. | Risk variants of alzheimer's disease |
| CA2825821A1 (en) | 2013-08-28 | 2015-02-28 | Chiesi Farmaceutici S.P.A. | 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| WO2016004389A2 (en) | 2014-07-03 | 2016-01-07 | Abbvie Inc. | Monovalent binding proteins |
| MX2017001531A (es) | 2014-08-08 | 2017-05-15 | Alector Llc | Anticuerpos anti-trem2 y metodos de uso de los mismos. |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| US10428143B2 (en) * | 2014-09-28 | 2019-10-01 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| WO2016064895A1 (en) * | 2014-10-20 | 2016-04-28 | The Brigham And Women's Hospital, Inc. | Targeting apolipoprotein e (apoe) in neurologic disease |
| KR20180002653A (ko) | 2015-04-07 | 2018-01-08 | 제넨테크, 인크. | 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법 |
| CA2986431C (en) | 2015-05-18 | 2020-04-14 | Synaptec Development Llc | Galantamine clearance of amyloid.beta. |
| WO2017011342A1 (en) | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| WO2017058866A1 (en) | 2015-09-28 | 2017-04-06 | Precision Immune, Inc. | Anti-trem2 antibodies and uses thereof |
| JP7725185B2 (ja) | 2015-10-06 | 2025-08-19 | アレクトル エルエルシー | 抗ｔｒｅｍ２抗体及びその使用方法 |
| KR102415925B1 (ko) * | 2016-01-11 | 2022-07-04 | 삼성디스플레이 주식회사 | 표시장치 |
| US11066456B2 (en) | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| US10941200B2 (en) | 2016-07-22 | 2021-03-09 | Deutsches Zentrum Für Neurodegenerative Erkrankungen Ev | TREM2 cleavage modulators and uses thereof |
| CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
| EP3570883A2 (en) | 2017-01-17 | 2019-11-27 | Yeda Research and Development Co. Ltd | Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells |
| US20190336615A1 (en) | 2017-01-27 | 2019-11-07 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| US10457717B2 (en) | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| US20190008812A1 (en) | 2017-07-07 | 2019-01-10 | Washington University | Methods for treating microglial dysfunction |
| AU2018307877A1 (en) | 2017-07-27 | 2020-01-02 | Novartis Ag | Sheddase resistant TREM2 variants |
| CN110662765B (zh) | 2017-08-03 | 2023-09-29 | 艾利妥 | 抗cd33抗体及其使用方法 |
| RS64419B1 (sr) | 2017-08-03 | 2023-09-29 | Alector Llc | Anti-trem2 antitela i postupci za njihovu upotrebu |
| US20200277373A1 (en) | 2017-09-14 | 2020-09-03 | Denali Therapeutics Inc. | Anti-trem2 antibodies and methods of use thereof |
| KR102709597B1 (ko) | 2017-10-03 | 2024-09-26 | 프리베일 테라퓨틱스, 인크. | 리소좀 장애를 위한 유전자 요법 |
| US20210186917A1 (en) | 2017-10-17 | 2021-06-24 | The Translational Genomics Research Institute | Trem2 agonists for the stimulation of microglia and methods of identification |
| EP3723803A4 (en) | 2017-12-12 | 2021-09-15 | Pionyr Immunotherapeutics, Inc. | ANTI-TREM2 ANTIBODIES AND RELATED PROCEDURES |
| WO2019161080A1 (en) | 2018-02-14 | 2019-08-22 | Yale University | Compositions for modulation of a trem or treml protein and methods of use |
| EP4126953A2 (en) * | 2020-04-03 | 2023-02-08 | Alector LLC | Methods of use of anti-trem2 antibodies |
| TW202306993A (zh) * | 2021-05-14 | 2023-02-16 | 美商建南德克公司 | Ｔｒｅｍ２之促效劑 |
-
2018
- 2018-08-02 RS RS20230644A patent/RS64419B1/sr unknown
- 2018-08-02 AU AU2018311055A patent/AU2018311055B2/en active Active
- 2018-08-02 CA CA3061755A patent/CA3061755A1/en active Pending
- 2018-08-02 KR KR1020197031793A patent/KR102769231B1/ko active Active
- 2018-08-02 CN CN202411407317.7A patent/CN119192376A/zh active Pending
- 2018-08-02 CR CR20190485A patent/CR20190485A/es unknown
- 2018-08-02 TW TW113146124A patent/TW202511296A/zh unknown
- 2018-08-02 EP EP18759461.9A patent/EP3601358B1/en active Active
- 2018-08-02 NZ NZ758301A patent/NZ758301A/en unknown
- 2018-08-02 UA UAA201910722A patent/UA129513C2/uk unknown
- 2018-08-02 CN CN201880027792.8A patent/CN110621696B/zh active Active
- 2018-08-02 EP EP23166216.4A patent/EP4248996A3/en active Pending
- 2018-08-02 KR KR1020257004632A patent/KR20250026882A/ko active Pending
- 2018-08-02 IL IL270235A patent/IL270235B2/en unknown
- 2018-08-02 SI SI201830958T patent/SI3601358T1/sl unknown
- 2018-08-02 MY MYPI2019006404A patent/MY201526A/en unknown
- 2018-08-02 SM SM20230281T patent/SMT202300281T1/it unknown
- 2018-08-02 FI FIEP18759461.9T patent/FI3601358T3/fi active
- 2018-08-02 LT LTEPPCT/US2018/045068T patent/LT3601358T/lt unknown
- 2018-08-02 IL IL315241A patent/IL315241A/en unknown
- 2018-08-02 HR HRP20230675TT patent/HRP20230675T1/hr unknown
- 2018-08-02 HU HUE18759461A patent/HUE062436T2/hu unknown
- 2018-08-02 DK DK18759461.9T patent/DK3601358T5/da active
- 2018-08-02 PT PT187594619T patent/PT3601358T/pt unknown
- 2018-08-02 CR CR20230170A patent/CR20230170A/es unknown
- 2018-08-02 WO PCT/US2018/045068 patent/WO2019028292A1/en not_active Ceased
- 2018-08-02 CN CN202411415268.1A patent/CN119192377A/zh active Pending
- 2018-08-02 CR CR20230169A patent/CR20230169A/es unknown
- 2018-08-02 TW TW107126810A patent/TWI811229B/zh active
- 2018-08-02 TW TW112126799A patent/TWI868807B/zh active
- 2018-08-02 PE PE2019002183A patent/PE20200148A1/es unknown
- 2018-08-02 MX MX2019012868A patent/MX2019012868A/es unknown
- 2018-08-02 BR BR112019022752-0A patent/BR112019022752A2/pt not_active Application Discontinuation
- 2018-08-02 MD MDE20200147T patent/MD3601358T2/ro unknown
- 2018-08-02 PL PL18759461.9T patent/PL3601358T3/pl unknown
- 2018-08-02 JP JP2019559017A patent/JP2020533948A/ja active Pending
- 2018-08-02 ES ES18759461T patent/ES2952982T3/es active Active
- 2018-08-03 US US16/054,680 patent/US10676525B2/en active Active
-
2019
- 2019-10-11 ZA ZA2019/06730A patent/ZA201906730B/en unknown
- 2019-10-28 MX MX2024001803A patent/MX2024001803A/es unknown
- 2019-10-28 CL CL2019003093A patent/CL2019003093A1/es unknown
- 2019-10-30 PH PH12019502459A patent/PH12019502459A1/en unknown
- 2019-10-30 CO CONC2019/0012210A patent/CO2019012210A2/es unknown
- 2019-10-31 EC ECSENADI201978429A patent/ECSP19078429A/es unknown
-
2020
- 2020-03-30 US US16/835,140 patent/US11634489B2/en active Active
- 2020-07-28 CL CL2020001974A patent/CL2020001974A1/es unknown
-
2022
- 2022-10-10 ZA ZA2022/11057A patent/ZA202211057B/en unknown
- 2022-11-22 JP JP2022186859A patent/JP7554247B2/ja active Active
-
2023
- 2023-02-24 US US18/174,499 patent/US20230312712A1/en active Pending
-
2024
- 2024-06-05 JP JP2024091312A patent/JP2024147536A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7554247B2 (ja) | 抗ｔｒｅｍ２抗体及びその使用方法 | |
| KR102733407B1 (ko) | 항-cd33 항체 및 이의 이용 방법 | |
| JP7586813B2 (ja) | 抗ｃｄ３３抗体及びその使用方法 | |
| KR20220127243A (ko) | 항-cd33 항체의 사용 방법 | |
| CN112512638B (zh) | 抗siglec-7抗体及其使用方法 | |
| HK40101643A (en) | Anti-trem2 antibodies and methods of use thereof | |
| HK40079770A (en) | Methods of use of anti-cd33 antibodies | |
| HK40019817B (en) | Anti-trem2 antibodies and methods of use thereof | |
| HK40019817A (en) | Anti-trem2 antibodies and methods of use thereof | |
| EA044134B1 (ru) | Анти-trem2 антитела и способы их применения | |
| HK40047633A (en) | Anti-siglec-7 antibodies and methods of use thereof | |
| HK40019112A (en) | Anti-trem2 antibodies and methods of use thereof |